Hypertrophic Cardiomyopathy — designated HCM, OMIM #192600 for the most common form, the most prevalent inherited cardiac condition affecting approximately 1 in 500 individuals worldwide (translating to roughly 700,000 Americans and 20 million people globally, making it far more common than most rare diseases while remaining profoundly underdiagnosed given that the majority of mutation carriers remain asymptomatic or minimally symptomatic for decades), caused in approximately 60% of genotype-positive cases by mutations in MYH7 (beta-myosin heavy chain) and MYBPC3 (myosin-binding protein C) — the two most prevalent sarcomere genes — with the remaining 40% of genetically confirmed cases attributable to mutations across at least 27 additional sarcomere and sarcomere-associated genes including TNNT2 (troponin T), TNNI3 (troponin I), TPM1 (alpha-tropomyosin), MYL2 (regulatory myosin light chain), MYL3 (essential myosin light chain), ACTC1 (cardiac actin), PLN (phospholamban), JPH2 (junctophilin-2), CSRP3, and FLNC, with approximately 30–40% of clinically definite HCM patients remaining genotype-negative despite comprehensive multigene panel testing — attributable to current limitations in variant interpretation, regulatory variants, polygenic contributions, copy number variants, and potential phenocopies from non-sarcomeric causes including PRKAG2 mutations, LAMP2 mutations (Danon disease), GLA mutations (Fabry disease), transthyretin amyloidosis (ATTR-CM), and mitochondrial cardiomyopathies that can produce HCM-like phenotypes requiring phenotype-specific therapeutic strategies; HCM is defined pathologically by unexplained left ventricular hypertrophy (typically asymmetric septal hypertrophy — ASH — with a septal-to-posterior wall thickness ratio exceeding 1.3:1, though concentric, apical, mid-ventricular, and right ventricular patterns exist) with a maximum LV wall thickness ≥15 mm (or ≥13 mm in first-degree relatives of a confirmed HCM proband) in the absence of another cardiac or systemic condition sufficient to explain the degree of hypertrophy, with the characteristic histopathological hallmarks of myocyte disarray — whirling, chaotic arrangements of individual myocytes and myofibrils replacing the normal parallel architecture — interstitial fibrosis, and abnormal intramural coronary arterioles with medial hypertrophy and reduced luminal diameter, producing the myocardial milieu for the dynamic left ventricular outflow tract (LVOT) obstruction present at rest or with provocation in approximately 70% of HCM patients (obstructive HCM — HOCM), the diastolic dysfunction with impaired relaxation and elevated filling pressures that produces exertional dyspnea, exercise intolerance, and eventually atrial fibrillation in 20–25% of HCM patients (AF representing a major HCM-specific stroke risk independent of CHA₂DS₂-VASc score), and the substrate for ventricular arrhythmias and sudden cardiac death that makes HCM the most common identified cause of sudden cardiac death in competitive athletes and young people under 35, with an annual SCD risk in unselected HCM cohorts of approximately 0.5–1% per year (reduced substantially from historical estimates of 3–6% per year in pre-ICD tertiary center cohorts, reflecting improved risk stratification and primary prevention ICD implantation in high-risk individuals) and a SCD risk exceeding 4–6% per year in patients with multiple high-risk features including prior cardiac arrest or sustained VT, family history of HCM-related SCD, unexplained syncope, extreme LV hypertrophy (maximum wall thickness ≥30 mm), hypotensive or attenuated blood pressure response to exercise, non-sustained VT on ambulatory monitoring, late gadolinium enhancement ≥15% of LV mass on cardiac MRI, and LVOT obstruction with peak gradient ≥30 mmHg; therapeutic advances in 2026 include cardiac myosin inhibitors — mavacamten (Camzyos, aficamten in development) — that reduce LVOT obstruction by directly modulating the number of myosin heads available for cross-bridge cycling (approved by FDA in 2022 for symptomatic obstructive HCM, with LVEF monitoring required given the mechanism-related risk of systolic dysfunction), alongside traditional therapies including beta-blockers and non-dihydropyridine calcium channel blockers for symptom control, disopyramide for refractory LVOT obstruction, septal reduction therapy — surgical myectomy (Morrow procedure, the gold standard for eligible patients at experienced HCM centers) or alcohol septal ablation (ASA, catheter-based alternative) — for severe drug-refractory obstructive symptoms, and heart transplantation for end-stage HCM with systolic dysfunction.
HCM technology platforms — encompassing the cardiac genetics platforms where sarcomere gene panel testing establishes the molecular diagnosis and enables family cascade screening, the echocardiography and cardiac MRI platforms where morphological characterization, LVOT gradient quantification, late gadolinium enhancement quantification for SCD risk stratification, and surveillance imaging are performed, the wearable and remote monitoring platforms where ambulatory ECG monitoring detects non-sustained VT, paroxysmal atrial fibrillation, and arrhythmia burden informs SCD risk stratification, the ICD management and remote telemonitoring platforms for primary and secondary prevention ICD recipients, the mavacamten prescribing and LVEF monitoring platforms where the REMS program REMS (Risk Evaluation and Mitigation Strategy) for cardiac myosin inhibitors requires mandatory LVEF reassessment before each prescription fill, the septal reduction therapy procedural platforms for surgical myectomy and alcohol septal ablation scheduling and follow-up, the heart failure management platforms for patients with HCM progressing to systolic dysfunction, the atrial fibrillation anticoagulation and ablation platforms for the 20–25% of HCM patients who develop AF, and the multidisciplinary HCM specialty center platforms at experienced HCM centers coordinating genetic counseling, SCD risk stratification, septal reduction therapy candidacy assessment, and competitive sports disqualification decisions — must maintain the availability and performance standards required by the SCD risk stratification protocols, ICD remote monitoring continuity, mavacamten REMS LVEF monitoring obligations, LVOT gradient-guided therapy adjustment workflows, AF anticoagulation management, and family cascade screening programs that define modern HCM management. This guide explains why HCM tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the SCD risk stratification complexity, ICD remote monitoring, cardiac myosin inhibitor REMS requirements, septal reduction therapy coordination, and genetic family cascade screening that define modern HCM care.
Why Hypertrophic Cardiomyopathy Tech Platforms Require Specialized Monitoring Attention
HCM management is defined by several uniquely urgent clinical management challenges: the sudden cardiac death risk stratification imperative — HCM SCD risk stratification is a nuanced, multifactorial calculation integrating family history, symptom history, maximum LV wall thickness, cardiac MRI late gadolinium enhancement burden, LVOT gradient, exercise hemodynamic response, and ambulatory arrhythmia monitoring requiring reliable access to multimodal diagnostic data across echocardiography, cardiac MRI, ambulatory monitoring, and electrophysiology platforms simultaneously; the mavacamten REMS monitoring obligation — mavacamten (Camzyos) is subject to a FDA-mandated REMS program requiring LVEF assessment before each 4-week prescription fill because mavacamten's myosin-head inhibitory mechanism carries an inherent risk of reducing LVEF below 50% requiring drug dose reduction or interruption, and a REMS platform failure preventing LVEF documentation before a refill could result in mavacamten dispensing in a patient with undocumented LVEF reduction; the ICD remote monitoring continuity requirement — HCM patients with primary prevention ICDs require remote telemonitoring for detecting VT/VF episodes, inappropriate shocks from T-wave oversensing or SVT with RVR, and lead integrity issues; and the competitive sports and driving restriction management — HCM SCD risk stratification directly informs sports participation decisions for young athletes, and the platforms documenting sports restriction counseling and SCD risk re-evaluation must be continuously accessible.
Cardiac genetics platforms confirm HCM sarcomere gene diagnosis and enable family cascade screening. MYH7 and MYBPC3 sequencing identifies the causative mutation in 60% of genotype-positive HCM cases, enables pre-symptomatic surveillance echocardiography in at-risk family members, and informs genetic counseling about the autosomal dominant 50% transmission risk. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Cardiac MRI platforms are central to HCM SCD risk stratification. Late gadolinium enhancement (LGE) quantification on cardiac MRI — with LGE ≥15% of LV mass now incorporated into major HCM SCD risk calculators as a major risk factor — requires reliable cardiac MRI scheduling, image acquisition, and reporting platforms. Monitor cardiac MRI platforms at 1-minute intervals during imaging hours.
ICD remote telemonitoring platforms require 24/7 availability. HCM patients with ICDs for primary prevention of SCD depend on remote monitoring for between-visit arrhythmia surveillance. ICD shock events require same-day review by the electrophysiology team. Monitor ICD platforms at 1-minute intervals, 24/7.
Mavacamten REMS platforms must be available to prescribers and pharmacists at dispensing checkpoints. The Camzyos REMS requires documented LVEF ≥50% before each 4-week prescription fill. A REMS platform failure preventing LVEF documentation confirmation at dispensing represents a patient safety risk. Monitor mavacamten REMS platforms at 1-minute intervals during pharmacy and clinical hours.
Septal reduction therapy platforms must support timely myectomy and alcohol ablation scheduling at HCM centers of excellence. Surgical myectomy and alcohol septal ablation are time-sensitive interventions for drug-refractory HOCM with limiting symptoms. Monitor procedural scheduling platforms at 1-minute intervals during clinical hours.
What to Monitor on a Hypertrophic Cardiomyopathy Tech Platform
Cardiac Genetics — Sarcomere Gene Panel
Monitor genetic testing referral records (clinical suspicion documentation — unexplained LV hypertrophy ≥15 mm or ≥13 mm in first-degree relatives of confirmed HCM proband; family history of HCM, unexplained SCD in a young relative, or known sarcomere mutation; newly diagnosed HCM at any age; phenocopy evaluation — ATTR-CM workup, Fabry disease alpha-galactosidase A activity, PRKAG2 assessment before comprehensive sarcomere panel), MYH7 and MYBPC3 sequencing records (pathogenic and likely pathogenic variant identification; MYBPC3 truncating variants — the most common HCM mutations — frameshift, nonsense, splice-site; MYH7 missense variants with clinical correlation; VUS documentation with variant database citation and plan for reclassification monitoring; genotype-negative documentation with recommendation for clinical surveillance), comprehensive HCM sarcomere gene panel records (27+ gene panels including TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, PLN, JPH2, CSRP3, FLNC; LAMP2 for Danon disease consideration in extreme hypertrophy in young males; GLA for Fabry disease; PRKAG2 for glycogen storage cardiomyopathy; TTR for transthyretin amyloidosis in older patients), family cascade screening records (surveillance echocardiography in first-degree relatives — annual or biennial echocardiography from age 12 through adulthood in relatives of confirmed HCM probands; targeted molecular testing for identified pathogenic sarcomere mutation), variant reclassification records (MYBPC3 and MYH7 VUS reclassification updates; functional data integration from ClinGen and ClinVar), and genetic counseling records (autosomal dominant penetrance counseling; age-dependent penetrance discussion — most sarcomere variant carriers who develop HCM phenotype do so in adolescence or early adulthood; sports participation implications for at-risk genotype-positive relatives pending surveillance echocardiography; reproductive counseling including preimplantation genetic testing options) at 1-minute intervals during laboratory hours.
SCD Risk Stratification and ICD Management
Monitor SCD risk stratification records (HCM Risk-SCD calculator documentation — 5-year SCD risk ≥6% as Class IIa ICD indication; ESC 2023 HCM guideline major risk factor integration — prior cardiac arrest or sustained VT, family history of SCD, maximum LV wall thickness ≥30 mm, unexplained syncope, hypotensive blood pressure response to exercise, LGE ≥15% LV mass, LVOT obstruction gradient ≥30 mmHg, non-sustained VT on Holter; AHA/ACC guideline risk factor documentation; annual risk re-stratification with updated cardiac MRI, echocardiography, and ambulatory monitoring), ICD implant and programming records (transvenous single-chamber, dual-chamber, or subcutaneous ICD selection and rationale; programming documentation for HCM — high-rate cut-off to avoid inappropriate shocks during AF with rapid ventricular response; T-wave oversensing screening for S-ICD in HCM patients with characteristic ECG morphology; VT detection zone documentation), remote telemonitoring records (all four major ICD manufacturers — Medtronic CareLink, Abbott Merlin.net, Boston Scientific LATITUDE, Biotronik Home Monitoring — transmission confirmation, VT/VF episode alerts, inappropriate shock alerts, lead integrity alerts), in-clinic device follow-up records (VT/VF episode review, shock appropriateness, programming optimization, battery projection, lead assessment), and inappropriate shock analysis records (AF with RVR causing inappropriate shock — anticoagulation and rate control optimization documentation; T-wave oversensing — reprogramming records) at 1-minute intervals, 24/7 for remote monitoring platforms. Alert immediately — ICD remote telemonitoring platform failures preventing same-day review of a VT/VF shock transmission from a 28-year-old HCM patient with a maximum LV wall thickness of 28 mm who received her first ICD shock at 11:15 PM while sleeping — when the electrophysiology team needs to determine whether this was an appropriate VF therapy or an inappropriate shock from T-wave oversensing or AF with RVR, and whether urgent medication adjustment, programming change, or AF ablation is indicated.
Cardiac Imaging — Echocardiography and Cardiac MRI
Monitor transthoracic echocardiography records (initial diagnostic echo — maximum wall thickness measurement at multiple segments; LVOT gradient at rest and with Valsalva provocation — LVOT gradient ≥30 mmHg at rest or ≥50 mmHg with provocation defining significant obstruction; mitral valve anatomy — systolic anterior motion of mitral valve leaflet producing LVOT obstruction; diastolic function assessment — E/e' ratio, LA volume index, pulmonary pressure estimation; LVEF assessment for systolic dysfunction surveillance), stress echocardiography records (exercise provocation of latent LVOT obstruction in patients with resting gradient <50 mmHg but exertional symptoms; hemodynamic blood pressure response to exercise), cardiac MRI records (LGE pattern and quantification — LGE ≥15% LV mass as major SCD risk factor; morphological characterization — apical HCM, mid-ventricular obstruction, LV aneurysm assessment; gadolinium agent administration records; myocardial perfusion assessment at CMRI centers), post-septal reduction therapy imaging records (LVOT gradient reassessment post-myectomy; alcohol septal ablation infarct zone size and gradient response; 6-month post-procedure echocardiography), and surveillance echocardiography records (annual echocardiography for asymptomatic HCM patients; biennial surveillance in genotype-positive phenotype-negative relatives) at 1-minute intervals during imaging hours. Alert immediately — cardiac MRI platform failures during LGE quantification for a 22-year-old male HCM patient with unexplained syncope, maximum LV wall thickness 26 mm, and non-sustained VT on ambulatory monitoring — when the electrophysiology team is calculating the HCM Risk-SCD score and the LGE percentage is the final determinant of whether the 5-year SCD risk crosses the threshold for ICD recommendation.
Mavacamten REMS and Cardiac Myosin Inhibitor Management
Monitor mavacamten REMS enrollment records (prescriber enrollment in the REMS program; patient enrollment; pharmacy enrollment; LVEF assessment documentation at baseline before initiation — LVEF must be ≥55% at initiation; concomitant drug interaction screening — mavacamten is CYP2C19 substrate with significant pharmacokinetic interactions with CYP2C19 inhibitors including pantoprazole, esomeprazole requiring dose reduction, and CYP2C19 inducers requiring dose increase), LVEF monitoring records before each prescription fill (LVEF documentation by echocardiography or CMRI within the REMS-specified window before each 4-week dispensing; LVEF ≥50% confirmation for continued dispensing; LVEF 40–50% documentation for dose reduction; LVEF <40% documentation requiring drug interruption and urgent cardiology follow-up), symptom response records (LVOT gradient reassessment on mavacamten — target reduction in peak LVOT gradient; functional status improvement — NYHA class change; exercise capacity improvement; symptom score improvement; drug discontinuation documentation with symptom rebound assessment), and drug safety surveillance records (LVEF reduction events and dose adjustment response; drug-drug interaction events; pregnancy exclusion documentation — mavacamten is a reproductive toxin requiring contraception in women of childbearing potential enrolled in the REMS) at 1-minute intervals during pharmacy and clinical hours.
Septal Reduction Therapy — Surgical Myectomy and Alcohol Septal Ablation
Monitor surgical myectomy scheduling records (candidate evaluation — severe drug-refractory HOCM with NYHA Class III-IV symptoms or exercise-induced syncope, peak LVOT gradient ≥50 mmHg at rest or provocation; experienced HCM center of excellence referral — surgical myectomy volume ≥10 per year as quality threshold; pre-operative cardiac catheterization records; intraoperative transesophageal echocardiography documentation — intraoperative LVOT gradient assessment, mitral valve repair if required), myectomy outcome records (post-operative LVOT gradient normalization; relief of systolic anterior motion; hospital stay and complication records — complete heart block requiring permanent pacemaker in approximately 1–2%, residual LVOT gradient requiring re-intervention), alcohol septal ablation records (candidate selection for ASA — septal anatomy favorable — target septal perforator branch identification on echo contrast injection; alcohol injection volume; creatine kinase rise documenting septal infarct; complete heart block requiring temporary pacing — 10% requiring permanent pacemaker; gradient response at 3 months and 12 months), and LVOT gradient surveillance records (pre- and post-reduction therapy gradient trajectory; residual obstruction surveillance with Valsalva provocation at annual follow-up) at 1-minute intervals during procedural hours.
Atrial Fibrillation and Anticoagulation Management
Monitor atrial fibrillation detection records (ambulatory ECG monitoring — paroxysmal AF detection in the 20–25% of HCM patients who develop AF; implanted loop recorder records for AF burden quantification; AF episodes in ICD remote monitoring transmissions), anticoagulation management records (AF in HCM — anticoagulation is recommended regardless of CHA₂DS₂-VASc score because HCM confers an intrinsic thromboembolic risk independent of conventional AF stroke risk factors; direct oral anticoagulant selection and dosing records; warfarin INR records if anticoagulated with warfarin; anticoagulation hold for procedure documentation), AF ablation records (pulmonary vein isolation for AF rhythm control in symptomatic HCM patients; combined AF ablation and myectomy at HCM centers; post-ablation AF recurrence monitoring), and rate control records (beta-blocker and non-dihydropyridine calcium channel blocker dosing for AF rate control with HOCM constraint — vasodilating antiarrhythmics that reduce afterload can exacerbate LVOT obstruction) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. HCM management coordinates across cardiology (echocardiography, LVOT gradient monitoring), cardiac genetics (sarcomere gene panel, family cascade screening), cardiac MRI (LGE quantification, SCD risk stratification), electrophysiology (ICD implantation, remote telemonitoring, AF ablation), cardiac surgery (surgical myectomy at HCM center of excellence), cardiac catheterization (alcohol septal ablation), pharmacy (mavacamten REMS dispensing, drug interaction screening), genetic counseling, sports medicine (competitive sports restriction counseling), and HCM specialty center coordination — authentication failures block every team member required to execute SCD risk stratification, ICD management, mavacamten REMS compliance, and septal reduction therapy decisions.
SSL Certificates
Monitor SSL certificate expiry across all cardiac genetics platforms, ICD remote telemonitoring portals, mavacamten REMS platforms, cardiac MRI scheduling systems, echocardiography reporting platforms, AF management portals, and HCM registry systems. Certificate errors disrupt ICD remote monitoring (most critically), REMS compliance documentation, cardiac imaging result delivery, and genetic testing portals.
HIPAA and Inherited Cardiomyopathy Privacy Considerations
HCM technology platforms handle sensitive PHI including sarcomere molecular genetic testing (autosomal dominant heritable mutation with 50% transmission risk to first-degree relatives; insurance discrimination risk under GINA for presymptomatic genotype-positive individuals; implications for competitive sports participation and career path decisions), cardiac MRI LGE quantification records (SCD risk stratification data whose unauthorized disclosure could affect life insurance, disability insurance, and employment in safety-sensitive occupations), ICD implant records (driving restrictions in most jurisdictions for the first 3–6 months after ICD implant and after any ICD shock, employment restriction implications for commercial drivers and pilots), mavacamten REMS enrollment records (medication restriction documentation implicating reproductive health data given the contraceptive requirement), and atrial fibrillation and anticoagulation records (anticoagulation requirement implicating bleeding risk in contact sports and safety-sensitive occupations). The heritable sarcomere mutation creates genetic information privacy obligations under GINA in addition to HIPAA Privacy and Security Rule requirements.
For ICD remote monitoring platforms — where unavailability delays detection of VT/VF episodes and inappropriate shocks between clinic visits — and for mavacamten REMS platforms — where unavailability creates a gap in the FDA-mandated REMS monitoring chain — availability monitoring provides operational documentation relevant to HIPAA Security Rule compliance and regulatory adherence.
Alerting Strategy for Hypertrophic Cardiomyopathy Tech Platforms
Immediate 24/7 alerting for ICD remote telemonitoring platforms: HCM ICD recipients depend on remote monitoring for arrhythmia detection between visits. VT/VF episodes and inappropriate shocks require same-day electrophysiology review.
Immediate clinical-hours alerting for mavacamten REMS platforms: LVEF documentation before each 4-week prescription fill is a REMS obligation. REMS platform failures create dispensing authorization gaps with patient safety and regulatory implications.
Immediate imaging-hours alerting for cardiac MRI platforms: LGE quantification on cardiac MRI is a major SCD risk stratification input. Imaging platform failures delay risk stratification decisions for at-risk patients.
Immediate laboratory-hours alerting for sarcomere gene panel platforms: Molecular confirmation guides family cascade screening, sports restriction counseling, and ICD decision-making in a clinically actionable timeframe.
Immediate clinical-hours alerting for echocardiography and LVOT gradient platforms: LVOT gradient quantification guides mavacamten dosing, septal reduction therapy candidacy, and post-procedure response assessment.
Immediate procedural-hours alerting for septal reduction therapy platforms: Surgical myectomy and alcohol septal ablation scheduling and intraoperative TEE platforms must function during active procedural windows.
Sustained-failure alert (10–15 minutes): AF anticoagulation management, genetic counseling scheduling, HCM patient registry, and sports restriction documentation platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms HCM platform availability from the geographies where HCM centers of excellence, sarcomere molecular genetic testing laboratories, high-volume myectomy programs, and ICD implanting electrophysiology centers operate.
Status Page for Hypertrophic Cardiomyopathy Care Team Communication
A real-time status page gives cardiologists quantifying LVOT gradients and adjusting mavacamten dosing, cardiac geneticists confirming sarcomere molecular diagnoses, electrophysiologists managing ICD programming and remote monitoring, cardiac surgeons performing myectomy procedures, interventional cardiologists performing alcohol septal ablation, cardiac MRI radiologists quantifying LGE burden, pharmacists managing mavacamten REMS dispensing authorization, sports medicine physicians advising on competitive sports restriction, genetic counselors managing family cascade screening, and HCM specialty center coordinators managing multidisciplinary SCD risk stratification immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in HCM patient education materials, mavacamten REMS contingency procedures, ICD remote monitoring backup protocols, and family cascade screening communication materials.
Vigilmon Setup for Hypertrophic Cardiomyopathy Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ICD remote telemonitoring (CareLink / LATITUDE / Merlin / Home Monitoring) | 1 min | Slack + PagerDuty (24/7) | | Mavacamten REMS LVEF documentation portal | 1 min | Slack + PagerDuty (clinical hours) | | Mavacamten REMS pharmacy dispensing authorization | 1 min | Slack + PagerDuty (pharmacy hours) | | Cardiac MRI scheduling and reporting | 1 min | Slack + PagerDuty (imaging hours) | | LGE quantification platform | 1 min | Slack + PagerDuty (imaging hours) | | Sarcomere gene panel (MYH7 / MYBPC3 / comprehensive panel) | 1 min | Slack + PagerDuty (lab hours) | | Echocardiography LVOT gradient reporting | 1 min | Slack + PagerDuty (imaging hours) | | ICD in-clinic device interrogation and programming | 1 min | Slack + PagerDuty (clinical hours) | | Surgical myectomy scheduling and intraoperative TEE | 1 min | Slack + PagerDuty (procedural hours) | | Alcohol septal ablation scheduling and catheterization lab | 1 min | Slack + PagerDuty (procedural hours) | | SCD risk stratification decision support | 2 min | Slack + PagerDuty (clinical hours) | | AF anticoagulation management | 2 min | Slack + PagerDuty (clinical hours) | | AF ablation scheduling | 2 min | Slack + PagerDuty (clinical hours) | | Family cascade screening (sarcomere relatives echocardiography + genetic) | 2 min | Slack + PagerDuty (clinical hours) | | HCM patient registry and sports restriction documentation | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ICD remote telemonitoring platforms (all manufacturers) with 24/7 immediate alerting — HCM ICD recipients require continuous between-visit arrhythmia surveillance
- Configure mavacamten REMS LVEF documentation portals with immediate clinical-hours alerting — REMS compliance requires LVEF documentation before each 4-week prescription fill
- Add mavacamten REMS pharmacy dispensing authorization platforms with immediate pharmacy-hours alerting
- Configure cardiac MRI scheduling and reporting platforms with immediate imaging-hours alerting — LGE quantification is a major SCD risk stratification input
- Add LGE quantification platforms with immediate imaging-hours alerting
- Configure sarcomere gene panel platforms with immediate laboratory-hours alerting
- Add echocardiography LVOT gradient reporting platforms with immediate imaging-hours alerting
- Configure ICD in-clinic device interrogation and programming with immediate clinical-hours alerting
- Add surgical myectomy and intraoperative TEE platforms with immediate procedural-hours alerting
- Configure alcohol septal ablation scheduling with immediate procedural-hours alerting
- Add SCD risk stratification decision support with sustained-failure alerting during clinical hours
- Configure AF anticoagulation management and ablation scheduling platforms with sustained-failure alerting during clinical hours
- Add family cascade screening platforms with sustained-failure alerting during clinical hours
- Configure HCM registry and sports restriction documentation platforms with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all ICD monitoring, genetics, cardiac MRI, REMS, echocardiography, and registry platforms
- Add the status page URL to HCM patient education materials and mavacamten REMS contingency procedures
Conclusion
Hypertrophic cardiomyopathy technology platforms are embedded in clinical decisions where ICD remote telemonitoring platform availability at 11:20 PM when a 24-year-old collegiate basketball player with HCM who received a primary prevention ICD 8 months ago due to a maximum LV wall thickness of 27 mm, non-sustained VT on Holter monitoring, and LGE quantified at 18% of LV mass experiences a 12-second episode of rapid polymorphic VT at rest that terminates spontaneously without ICD therapy — which is transmitted by the home monitor as an unsustained arrhythmia episode — cannot be disrupted by remote telemonitoring platform failures that prevent the electrophysiology team from reviewing this subclinical near-miss arrhythmia overnight, determining whether the detection zone needs reprogramming, and scheduling an urgent next-morning clinic visit to reassess the patient's overall risk and consider whether she should be suspended from training pending medication adjustment; where mavacamten REMS platform availability during the pharmacy dispensing check for a 51-year-old obstructive HCM patient who has experienced dramatic LVOT gradient reduction from 85 mmHg to 18 mmHg on mavacamten 5 mg with relief of his NYHA Class III exertional dyspnea — when the pharmacist processing his monthly refill requires REMS-confirmed LVEF documentation from the echocardiogram performed 12 days ago — cannot be disrupted by REMS platform failures that halt the dispensing authorization process and leave the patient without a medication whose abrupt discontinuation would produce rebound LVOT obstruction and symptom recurrence; and where cardiac MRI LGE quantification platform availability during the SCD risk stratification evaluation of a 19-year-old asymptomatic HCM patient with a maximum LV wall thickness of 22 mm, a family history of HCM-related SCD in a 31-year-old first cousin, non-sustained VT in the last 48 hours of a 2-week Holter monitor, and no prior cardiac MRI — when the HCM specialist needs the precise LGE percentage to complete the HCM Risk-SCD calculation and determine whether the 5-year SCD risk crosses the 6% threshold for a Class IIa ICD recommendation in this asymptomatic teenager — cannot be disrupted by cardiac MRI platform failures that delay risk stratification in a patient with multiple accumulating risk factors converging toward the ICD threshold. An ICD remote telemonitoring platform unavailable when a young HCM patient's near-miss nocturnal arrhythmia goes undetected, a mavacamten REMS platform failed when a patient cannot access refill authorization for the cardiac myosin inhibitor providing life-quality transformation of his obstructive HCM, a cardiac MRI LGE quantification platform inaccessible when the final risk stratification variable is being calculated in a teenager approaching the ICD decision threshold — these are not IT incidents. They are clinical disruptions in the management of the most common inherited cardiac condition, where sarcomere gene mutations produce myocardial disarray and arrhythmic substrate from adolescence, dynamic outflow obstruction responds to precisely monitored cardiac myosin inhibition, and SCD risk stratification accuracy determines whether a 19-year-old receives a prophylactic device or continues without one — making ICD remote monitoring continuity, REMS compliance precision, and cardiac MRI availability the operational foundations on which HCM mortality risk reduction and quality of life improvement are built.
Uptime monitoring gives HCM tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to HCM specialty centers, cardiac electrophysiology programs, ICD device clinic operations, sarcomere molecular genetic testing laboratories, mavacamten REMS compliance officers, cardiac MRI programs, HCM myectomy centers, and compliance auditors that platform operational reliability matches the continuous remote monitoring precision, REMS monitoring obligations, cardiac imaging urgency, and genetic family cascade screening responsibilities of modern hypertrophic cardiomyopathy care.
Start monitoring your hypertrophic cardiomyopathy care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #hypertrophic #cardiomyopathy #HCM #HOCM #sarcomere #MYH7 #MYBPC3 #LVOT #obstruction #ICD #sudden #cardiac #death #SCD #risk #stratification #mavacamten #Camzyos #REMS #LVEF #myectomy #alcohol #septal #ablation #LGE #cardiac #MRI #atrial #fibrillation #genetic #cascade #screening #HIPAA #healthtech #digitalhealth #uptime #sre